Kymera raises $65M from global syndicate as it aims for the clinic with protein degradation tech
You can add Kymera Therapeutics to the list of biotechs attracting attention from an international set of investors.
The biotech is taking the lid off a $65 million round that’s been put together to help steer the discovery-stage company toward the clinic — a landmark affair for Kymera that isn’t going to arrive ahead of 2020.
Incubated by Atlas and blessed with a $30 million launch round a year ago — after starting up with seed funding in LabCentral in Cambridge, MA — Kymera now has the cash to grow the team and the pipeline of preclinical programs. Like others in the field, their scientists are focused on hijacking the body’s ubiquitin-proteasome system to dispose of proteins, binding to proteins and marking them for destruction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
